IP Verse

Deuterated Derivatives Of Ruxolitinib

Patent No. EP3450434 (titled "Deuterated Derivatives Of Ruxolitinib") was filed by Concert Pharmaceuticals on Jun 14, 2013. The application was issued on Feb 24, 2021.

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
INCYTENov 23, 2021CARPMAELS & RANSFORD

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP3450434

CONCERT PHARMACEUTICALS
Application Number
EP18188152A
Filing Date
Jun 14, 2013
Status
Granted And Under Opposition
Jan 22, 2021
Publication Date
Feb 24, 2021
External Links
Slate, Register , Google Patents